{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T02:08:02Z","timestamp":1761790082409,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR002344"],"award-info":[{"award-number":["TL1TR002344"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK52574"],"award-info":[{"award-number":["DK52574"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL151328"],"award-info":[{"award-number":["HL151328"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10620-023-07980-8","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T16:01:36Z","timestamp":1686240096000},"page":"3451-3457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low LDL Cholesterol Is Not an Independent Risk Factor for Hepatic Steatosis"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-0345","authenticated-orcid":false,"given":"Scott","family":"McHenry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameen","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kozlitina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan O.","family":"Stitziel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas O.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"7980_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7980_CR2","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/metabo11100690","volume":"11","author":"J Behbodikhah","year":"2021","unstructured":"Behbodikhah J, Ahmed S, Elyasi A et al. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites 2021;11:690.","journal-title":"Metabolites"},{"key":"7980_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020;69:1691\u20131705.","journal-title":"Gut"},{"key":"7980_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/hep.31229","volume":"72","author":"S Sookoian","year":"2020","unstructured":"Sookoian S, Pirola CJ, Valenti L et al. Genetic pathways in nonalcoholic fatty liver disease: insights from systems biology. Hepatology 2020;72:330\u2013346.","journal-title":"Hepatology"},{"key":"7980_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018;68:268\u2013279.","journal-title":"J Hepatol"},{"key":"7980_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-981-15-6082-8_4","volume":"1276","author":"J Iqbal","year":"2020","unstructured":"Iqbal J, Jahangir Z, Al-Qarni AA. Microsomal triglyceride transfer protein: from lipid metabolism to metabolic diseases. Adv Exp Med Biol 2020;1276:37\u201352.","journal-title":"Adv Exp Med Biol"},{"key":"7980_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jhep.2014.05.023","volume":"61","author":"M Di Filippo","year":"2014","unstructured":"Di Filippo M, Moulin P, Roy P et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. J Hepatol 2014;61:891\u2013902.","journal-title":"J Hepatol"},{"key":"7980_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.atherosclerosis.2017.11.033","volume":"268","author":"TT Li","year":"2018","unstructured":"Li TT, Li TH, Peng J et al. TM6SF2: a novel target for plasma lipid regulation. Atherosclerosis 2018;268:170\u2013176.","journal-title":"Atherosclerosis"},{"key":"7980_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46:352\u2013356.","journal-title":"Nat Genet"},{"key":"7980_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng.2926","volume":"46","author":"OL Holmen","year":"2014","unstructured":"Holmen OL, Zhang H, Fan Y et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014;46:345\u2013351.","journal-title":"Nat Genet"},{"key":"7980_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/hep.27556","volume":"61","author":"S Sookoian","year":"2015","unstructured":"Sookoian S, Castano GO, Scian R et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 2015;61:515\u2013525.","journal-title":"Hepatology"},{"key":"7980_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/hep.31771","volume":"74","author":"EP Newberry","year":"2021","unstructured":"Newberry EP, Hall Z, Xie Y et al. Liver-specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis, and hepatocellular cancer. Hepatology 2021;74:1203\u20131219.","journal-title":"Hepatology"},{"key":"7980_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/liv.14711","volume":"41","author":"S Grimaudo","year":"2021","unstructured":"Grimaudo S, Bartesaghi S, Rametta R et al. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. Liver Int 2021;41:321\u2013332.","journal-title":"Liver Int"},{"key":"7980_CR14","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol 2017;69:2054\u20132063.","journal-title":"J Am Coll Cardiol"},{"key":"7980_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/hep.30874","volume":"71","author":"CL Jansson-Knodell","year":"2020","unstructured":"Jansson-Knodell CL, Gawrieh S, McIntyre AD et al. Apolipoprotein B and PNPLA3 double heterozygosity in a father\u2013son pair with advanced nonalcoholic fatty liver disease. Hepatology 2020;71:383\u2013385.","journal-title":"Hepatology"},{"key":"7980_CR16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jacl.2014.08.002","volume":"8","author":"N Hashemi","year":"2014","unstructured":"Hashemi N, Odze RD, McGowan MP et al. Liver histology during Mipomersen therapy for severe hypercholesterolemia. J Clin Lipidol 2014;8:606\u2013611.","journal-title":"J Clin Lipidol"},{"key":"7980_CR17","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387\u20131395.","journal-title":"Hepatology"},{"key":"7980_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.020","volume":"18","author":"S McHenry","year":"2020","unstructured":"McHenry S, Park Y, Browning JD et al. Dallas steatosis index identifies patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2020;18:e7.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7980_CR19","doi-asserted-by":"publisher","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","volume":"288","author":"LS Szczepaniak","year":"2005","unstructured":"Szczepaniak LS, Nurenberg P, Leonard D et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462\u2013E468.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"7980_CR20","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1161\/ATVBAHA.112.301101","volume":"33","author":"AB Cefalu","year":"2013","unstructured":"Cefalu AB, Pirruccello JP, Noto D et al. A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler Thromb Vasc Biol 2013;33:2021\u20132025.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7980_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/MEG.0b013e3282ffd9f8","volume":"21","author":"D Bonnefont-Rousselot","year":"2009","unstructured":"Bonnefont-Rousselot D, Condat B, Sassolas A et al. Cryptogenic cirrhosis in a patient with familial hypocholesterolemia due to a new truncated form of apolipoprotein B. Eur J Gastroenterol Hepatol 2009;21:104\u2013108.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"7980_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa061189","volume":"356","author":"M Cuchel","year":"2007","unstructured":"Cuchel M, Bloedon LT, Szapary PO et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148\u2013156.","journal-title":"N Engl J Med"},{"key":"7980_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.atherosclerosissup.2014.07.005","volume":"15","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Blom DJ, Averna MR. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Atheroscler Suppl 2014;15:33\u201345.","journal-title":"Atheroscler Suppl"},{"key":"7980_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jacl.2020.12.010","volume":"15","author":"E Vilar-Gomez","year":"2021","unstructured":"Vilar-Gomez E, Gawrieh S, Liang T et al. Interrogation of selected genes influencing serum LDL-cholesterol levels in patients with well characterized NAFLD. J Clin Lipidol 2021;15:275\u2013291.","journal-title":"J Clin Lipidol"},{"key":"7980_CR25","doi-asserted-by":"publisher","first-page":"100066","DOI":"10.1016\/j.xgen.2021.100066","volume":"1","author":"ME Haas","year":"2021","unstructured":"Haas ME, Pirruccello JP, Friedman SN et al. Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genom 2021;1:100066.","journal-title":"Cell Genom"},{"key":"7980_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001324","volume":"7","author":"EK Speliotes","year":"2011","unstructured":"Speliotes EK, Yerges-Armstrong LM, Wu J et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324.","journal-title":"PLoS Genet"},{"key":"7980_CR27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","volume":"61","author":"RC Adam","year":"2020","unstructured":"Adam RC, Mintah IJ, Alexa-Braun CA et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J Lipid Res 2020;61:1271\u20131286.","journal-title":"J Lipid Res"},{"key":"7980_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/MOL.0000000000000663","volume":"31","author":"FK Welty","year":"2020","unstructured":"Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease. Curr Opin Lipidol 2020;31:49\u201355.","journal-title":"Curr Opin Lipidol"},{"key":"7980_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37:161\u2013165.","journal-title":"Nat Genet"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07980-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-07980-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07980-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T03:38:07Z","timestamp":1689651487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-07980-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["7980"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-07980-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no potential personal consultant, institutional or financial conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Dallas Heart Study was approved by the University of Texas Southwestern Medical Center IRB and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments with informed written consent. Secondary data analysis was then performed with approval by the Washington University Human Research Protection Office (IRB number 201905162) after the analysis of the de-identified data was determined to be nonhuman subject\u2019s research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}